Spinal fusion material, BMP, increases risk of benign tumors, not cancer

Spinal fusion material, BMP, increases risk of benign tumors, not cancer

Using a certain bone grafting material for spinal fusion, one of the most common procedures for people with painful vertebral deteriorations, does not appear to result in higher rates of cancer, according to researchers at Duke Medicine.

However, the researchers found that the bone promoter known as recombinant human 2, or BMP, is associated with a higher rate of in the brain and nervous system.

Reported in the September 2013, print edition of the journal Neurosurgery, the finding provides a better understanding of the long-term outcomes of spinal fusions using BMP. Recent studies have suggested that the is associated with harmful effects, including increased rates of cancer when used in high doses, leading to a decision by the U.S. Food and Drug Administration to reject approval of the higher dosage formulation.

Although BMP is approved only for use in the lower spine with anterior approaches for surgery, it has been widely used "off-label" in cervical fusions, posterior lumbar procedures, and minimally invasive approaches.

"Given the widespread use of BMP, there has been a tremendous need for better data about its effects," said lead author Nandan Lad, M.D., Ph.D., assistant professor in the division of neurosurgery at Duke University School of Medicine. "Our study is the largest to date examining the association between BMP use and cancer."

Using national claims data from commercial insurers, Medicaid and Medicare, Lad and colleagues conducted a large, of more than 4,600 patients who had undergone spinal fusions with BMP and matched them against similar patients who had the procedure without the material. They examined the association between BMP and the general risk of cancer, as well as the risk of developing cancer in different tissues.

Overall, the Duke-led team found that 9.4 percent of patients receiving BMP developed malignant cancers, compared to 8.4 percent of patients not receiving the growth factor – a difference that was not statistically significant.

For benign tumors, there was a significantly higher risk. After adjusting to better match patients in both groups to eliminate selection bias, the researchers found that those who received BMP were 31 percent more likely to be diagnosed with benign tumors than those who did not receive the graft material. These tumors included non-malignant growths in the brain and nervous system.

"While the absolute risks were small overall, the increased risk for soft tissue tumors and those lining the nervous system among patients receiving BMP may be caused by the large local dose of BMP that is administered to the spine, and warrants further study," Lad said.

Lad said findings should be viewed with caution, noting that the limitations of the study include its retrospective design. However, the ethical and practical complications of prospectively enlisting patients in a head-to-head comparison of BMP against no growth factor made a large, retrospective study the next-best approach. Lad said the study also relies on accurate and timely diagnoses of cancer and benign tumors among the study population.

"We believe this study is the first to specifically investigate the association between the use of BMP and risk in a systematic manner, and apply it to the general population of undergoing spinal fusion in the United States," Lad said.

add to favorites email to friend print save as pdf

Related Stories

Complications rise along with off-label use of BMP-2

Sep 06, 2010

When the U.S. Food and Drug Administration in 2002 approved a product many thought would revolutionize back surgery, the agency did so despite concerns the product might cause serious side effects.

Study finds increased cancer risk with bone growth product

Nov 04, 2011

Spine surgery patients who got a bone growth stimulating agent as part of a clinical trial were three to five times more likely to develop cancer two to three years after being implanted with the product, according to a new ...

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.